Thyrocare Technologies Limited — PPTs, 28-01-2026: Investor Presentation

Thyrocare delivered a strong Q3 FY26 performance. Consolidated revenue surged 18% YoY to ₹195.5 Cr, with PAT jumping 47% YoY to ₹27.9 Cr. Normalized EBITDA grew 26% YoY to ₹62.2 Cr, marking a 32% margin. Pathology revenue, up 20% YoY, was primarily driven by robust 39% YoY growth in partnership revenue and 12% YoY in franchise revenue. The company saw a 14% rise in patients to 0.45 Cr and a 22% increase in tests to 4.96 Cr. A strategic move to manage credit led to a 50% reduction in Vimta franchisee revenue.

Key strategic pillars include expanding deeper into India with focused test menus, strengthening the franchise network, and growing partnerships in areas like insurance and ECG at home. International expansion in Tanzania is also a priority. Recent highlights include naming Madhuri Dixit as brand ambassador, winning the National Diagnostics Champion award, and opening new labs in Davangere and Mandi to bolster its pan-India presence. The company remains committed to its B2B model for affordable diagnostics. Note that Normalized EBITDA is a key performance indicator due to non-cash ESOP charges.